Modus Therapeutics Holding AB
Research Modus Therapeutics Holding AB (MODTX) on Bullrun: market cap SEK 56.36M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMODTX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 56.36M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 3.28M
- Free cash flow-SEK 4.44M
Valuation Snapshot
latest market cap is SEK 56.36M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 18.54M | -SEK 18.08M | n/a | -0.22 | SEK 11.37M | SEK 0 | SEK 9.07M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | SEK 56.36M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Modus Therapeutics Holding AB's market cap?
Modus Therapeutics Holding AB's market capitalization is SEK 56.36M.
What does Modus Therapeutics Holding AB do?
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.